Get started
Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CPRX trade ideas

CPRX Growth Stock with Favorable UpsideCatalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ): Growth Stock with Favorable Upside Trade Setup: - Buy Price: $21.31 - Stop-Loss: $19.31 - Take-Profit Targets: - TP1: $25.32 - TP2: $30.22 Rationale: Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focusing on innovative therapies for rare neurological diseases. The company's solid revenue growth and market position in niche segments offer a compelling reason for potential upside. Financial Performance: - In Q3 2024, the company reported **revenue of $128.7 million**, a **25.3% increase year-over-year**, driven by strong demand for their lead product, FIRDAPSE®, and the successful U.S. launch of AGAMREE®. - Net income improved to **$45.6 million**, compared to $35.2 million in the same period last year. Analyst Ratings: - Catalyst Pharmaceuticals has a consensus **"Strong Buy" rating** from analysts. - The average price target is **$31.14**, suggesting a potential upside of approximately 46% from the current price. Volume and Market Dynamics: - Short interest sits at around **7.47%**, signaling moderate bearish positioning but also potential for a short squeeze if bullish momentum builds. - Trading volumes have shown steady growth, reflecting increased investor interest. Risk/Reward Analysis: With a stop-loss at $19.31, the risk is approximately **$2 per share** from the entry price. The first take-profit target offers a reward of **$4 per share** and the second target extends it to **$9 per share**, creating a favorable risk-to-reward ratio of **1:2** and **1:4.5**, respectively. Conclusion: Catalyst Pharmaceuticals presents a balanced opportunity for growth-oriented traders. While short interest and volatility indicate some risk, strong financial performance and favorable analyst targets provide confidence in the stock’s potential. When the Market’s Call, We Stand Tall. Bull or Bear, Just Ride the Wave! *Disclaimer: This analysis is for informational purposes only and does not constitute financial advice. Traders should conduct their own due diligence before making investment decisions.*
NASDAQ:CPRXLong
by SiriusTrading
The same idea....look my other postsWhile I remain long-term bullish on CPRX, the current price level seems elevated, and there are signs suggesting a pullback is imminent. The RSI indicates that the stock has been overbought, and we may see a correction soon. I'm closely watching the Fibonacci retracement at 0.618, which has proven to be a strong resistance level over the past 9 months. This area around $18.50 could offer solid support, and I plan to start buying when we reach that level. However, it's important to note the gap in the chart. As we know, gaps tend to get filled eventually, so I wouldn't be surprised if the price dips further before finding a stronger base. Despite this short-term outlook, I'm confident we're in a favorable position overall, and my long-term forecast for CPRX remains bullish.
NASDAQ:CPRXShort
by csokasilevente3
Make a good decision, and realize your profit.Make a good decision, and realize your profit. You can see my oldest ideas, I was always bullish on this stock, and I still am. On August 7 they report the second quarter, and I expect good numbers. Those who follow the company management expect the same, I think. But they are greedy, I am greedy too, I want to get my profit. You can see the signs on the chart, I marked the RSI momentums. When the RSI 70 was crossed you got the sell sign. This was in the last 12 months. On the other hand, the 17.60 level looks like a strong resistance. The MACD only confirms my theory. I expect falling in the next two weeks, a falling around 10%. We are in a bullish trend in the long term, I am sure the trend will continue, this 10% fall is just the reward for our patience.
NASDAQ:CPRXShort
by csokasilevente3
Long term stock idea: CPRX (Small Cap Biotech) When markets are messy I like to explore long term bases in relatively unknown stocks. CPRX has a 15 year base with contracting volatility in recent years, mostly since 2019. I like the look of the quarterly chart and I like the volume markers on the daily - institutional funds have been progressively accumulating. As all biotech stocks are highly speculative, position size needs to be taken down accordingly. This trade looks like the type of set-up that can be a multi-year hold if the stop is wide enough.
NASDAQ:CPRXLong
by Lanmar
9
Long trade in CPRXCPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith. Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters. The stock made a false breakout on December 14 when the market gapped up on CPI data. It then put in a shakeout move to hit stops before rallying right out of its base. I am taking a small position in the stock here with a tight stop at 17.65. I want to see new highs in the next several days to confirm the breakout has legs.
NASDAQ:CPRXLong
by rossgivens
Is $CPRX ready to break out of its cup and handle?Notes: * Strong up trend * Okay earnings track record * Basing for the past ~8 weeks * Pulled back to its 10 week line and managed to hold it as support creating a cup and handle pattern * Printed a pocket pivot near its 50 day line offering an early entry and indicating institutional demand Technicals: Sector: Healthcare - Biotechnology Relative Strength vs. Sector: 23.86 Relative Strength vs. SP500: 4.28 U/D Ratio: 1.21 Base Depth: 45.07% Distance from breakout buy point: -18.82% Volume 14.75% above its 15 day avg. Trade Idea: * You can enter now as the price is rising with higher than average volume off of its 50 EMA * Another reason for entering would be that it printed a pocket pivot * If you want to play it a bit safe you can wait for a break out of the indicated channel and the 14.3 area since that may serve as immediate resistance
NASDAQ:CPRXLong
by HaseebKhan_90
Where I'm Buying CPRXCatalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months. There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart). After such a large advance higher, we must remain cautious to the possibility of a retracement. So we need to see signs of additional strength to trigger an entry. I’m watching for a move above last week’s high for my buy signal. This way, I can place a stop below last week’s low and still get away with a risk of 8% or less on the trade.
NASDAQ:CPRXLong
by rossgivens
$CPRX coming up on the right side of its base!Notes: * Strong up trend * Not the best earnings * Tested historical resistance of $6.17 around mid June * Broke and retested historical resistance of $7.43 just recently * Printed a pocket pivot and is still relatively close to its 50 day line * The Healthcare sector is doing relatively well compared to others Technicals: Sector: Healthcare - Biotechnology Relative Strength vs. Sector: 1.77 Relative Strength vs. SP500: 1.41 U/D Ratio: 1.59 Base Depth: 38.68% Distance from breakout buy point: -10.42% Volume 62.59% above its 15 day avg. Trade Idea: * You can enter now as the price is still close to its 50 day line and the price is just bouncing off of historical resistance with higher than average volume. * If you're looking for a better entry you can look for one around the $7.62 area * This stock usually has local tops when the price closes around 21.31% above its 50 EMA * Consider selling into strength if the price closes 21.11% to 21.51% (or higher) above its 50 EMA * The last closing price is 8.25% away from its 50 EMA
NASDAQ:CPRXLong
by HaseebKhan_90
CPRX(NASDAQ:CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%. And in the coming years, that revenue could grow even more. Now, Catalyst is focused on expanding Firdapse's approved indications to cover more populations of patients with LEMS, starting with children. At the same time, the company is developing an extended-release version of Firdapse, which will be preferable for patients and potentially command a higher selling price too. It's also working to commercialize Firdapse in Japan, starting early next year with a small registrational clinical trial that'll pave the way for larger investigations. Opening up new markets outside of the U.S. and Canada could be huge, as LEMS is so rare that only one in 100,000 people has it -- and Catalyst is the only company working on treatments. The main challenge will be finding markets where the disease is known enough to be consistently diagnosed. So, Catalyst's decision to target Japan is a good one, as the country has a high concentration of healthcare resources which should ensure that people with LEMS are both findable and treatable with Firdapse. Eventually, scaling the business to reach all of the LEMS patients in the entire world isn't something that's too far-fetched. Aside from its soon-to-be-expanding indications and its foray into foreign markets, the stock is priced to perfection. Its trailing price-to-earnings (PE) ratio is 18, which is vastly lower than the wider market's average near 30. Also, looking for a bounce, then a breakout up.
NASDAQ:CPRXLong
by Sc00byTrades
Price Action Analysis for CPRXHello Traders! CPRX was making a pull back and would expect a nice bounce at the strong support level after a strong bullish reversal candle. What I did to this analysis: 1. I Draw Major Support/Resistance in Weekly Time frame 2. Find trend - Higher High, Higher Low 3. Find a pullback in price 4. Wait for the Strong Reversal Candle at Support Level In trading you need to have rules and be strict to it before entering any trades. Hope you enjoy my analysis and hope you smash the like button
NASDAQ:CPRXLong
by The_Power_of_Price_Action
CPRX Catalyst Pharmaceuticals $40M Repurchase P/E Ratio 6.5 WOWCatalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com) The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share. The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com) CPRX it`s an easy 50% in my opinion. $40 Million Share Repurchase. Market Cap 453.715M. PE Ratio (TTM) 6.15. 75mil revenue, 119mil earnings in 2020 haven`t seen such a great balance sheet on a penny stock. now trading at 4,94usd. 3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00 H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9 If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:CPRXLong
by TopgOptions
11